Perioperative cardioprotection in noncardiac surgery: realities and prospects

Kozlov, I. A.

doi:10.17116/anaesthesiology2020041100

Anaes. i reanim.

2020

DOI: 10.17116/anaesthesiology2020041100

|View full text |Cite

Perioperative cardioprotection in noncardiac surgery: realities and prospects

I. A. Kozlov¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Use of exogenic phosphocreatine in ICU rehabilitation of patients with COVID-19 (pilot study)

Krapivina

Voevodin

Черняк

et al. 2021

Vestn. anesteziol. reanimatol.

View full text Add to dashboard Cite

The objective: to establish the possible effectiveness of exogenous phosphocreatine as a component of pharmacological support during the resuscitation stage of rehabilitation measures in critically ill patients with COVID-19.Subjects and Methods. Within a randomized study, 21 patients diagnosed with COVID-19 were divided into two groups: Group 1 (patients received the infusion of exogenous phosphocreatine as part of intensive care) and Group 2 (patients received standard intensive care) against the background of rehabilitation measures. Patients were assessed for muscle strength using the MRC scale, exercise tolerance by Borg rating, oxygenation parameters, routine clinical laboratory blood tests, dependence on respiratory support, outcome on day 10 of therapy, and hospital outcome.Results. The effectiveness of the use of the exogenous phosphocreatine as a component of pharmacological support during the resuscitation stage of rehabilitation measures in critical patients has been confirmed by positive dynamics: an increase in muscle strength (the MRC score in the group receiving exogenous phosphocreatine on day 10 was 0.5 points higher) and an increase in exercise tolerance (Borg rating in the group receiving exogenous phosphocreatine on day 10 was 1.5 points higher), significant increase in oxygenation based on arterial blood saturation data, and significant increase in lymphocyte count by 25% in the group receiving exogenous phosphocreatine.Conclusion. Exogenous phosphocreatine is a candidate drug for pharmacological support during resuscitation stage of rehabilitation of critical patients with COVID-19.

show abstract

Use of exogenic phosphocreatine in ICU rehabilitation of patients with COVID-19 (pilot study)

Krapivina

Voevodin

Черняк

et al. 2021

Vestn. anesteziol. reanimatol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Perioperative cardioprotection in noncardiac surgery: realities and prospects

Cited by 1 publication

References 63 publications

Use of exogenic phosphocreatine in ICU rehabilitation of patients with COVID-19 (pilot study)

Use of exogenic phosphocreatine in ICU rehabilitation of patients with COVID-19 (pilot study)

Contact Info

Product

Resources

About